Introduction
In addition to tumor necrosis factor-a (TNF-a), interleukin (IL)-1b and IL-6, the role of IL-12 in the pathogenesis of acute GVHD (aGVHD) has also been reported in experimental and clinical studies. [1] [2] [3] [4] [5] Sykes et al. 6 and Yang 7 have shown that IL-12 has a major role in the development of aGVHD and have also observed that IL-12 levels rose at approximately 7-10 days post transplant, that is, shortly before the expected onset of aGVHD in their model. This effect was dependent on IL-12 stimulation of IFN-g by T-helper 1 (Th1) T cells. Recently, some of the reported effects of IL-12 have been called into question because it is now known that another member of the IL-12 family, IL-23, may be more responsible for some of the alleged phenomena. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] IL-23 is produced by several non-lymphocyte populations, including macrophages, dendritic cells and keratinocytes. 17 The reported data indicate that IL23p19 is closely associated with inflammation in multiple sclerosis, 15 rheumatoid arthritis, 16 colonic epithelium, 18 and in models of experimental autoimmune encephalitis, 13 colitis 14 and arthritis. 19 Other studies have now shown that it may also have a significant role in cancer control. 20 IL-12 and IL-23 are heterodimers, both of which share a p40 dimer but differ by IL-12p35 and IL-23p19. 21 The role of IL-23 to maintain Th17 cells has been shown to be related to its unique dimer, p19, and not the p40 dimer. It now appears that the reported functions of IL-23 in autoimmune disease are related to the p19 dimer. 13 As many of the inflammatory reactions of IL-23p19 14, [19] [20] [21] [22] [23] [24] [25] [26] [27] are also associated with IL-17, a new axis of inflammation, IL23p19/IL-17, has been proposed. 28 To date, not much information has been published on the roles of IL-23p19 and IL-17, but there is an increasing interest in their importance in both solid organ transplantation [29] [30] [31] [32] [33] [34] and SCT. [35] [36] [37] [38] [39] The availability of targeted mutant p19À/À mice of C57Bl/6 (hereafter B6) background provided a unique opportunity to test this hypothesis. We reasoned that deficiency of p19 in the allogeneic donor transplant would reduce the severity of aGVHD. 40 The data herein confirm this hypothesis and provide information regarding the mechanisms for this improvement.
Materials and methods

Animals
Male BALB/c major histocompatibility complex-2 (H2 d ) and B6 H2 b mice were obtained from Jackson Laboratories (Bar Harbor, MI, USA). After receipt, they were held for 1 or 2 weeks until they were 9 to 10 weeks of age. B6 mice were chosen for their major histocompatibility complex incompatibility with BALB/c mice. Breeding pairs of IL-23p19À/À mutant (hereafter called p19À/À or p19-deficient) mice were kindly provided by Dr Daniel Cua (Sherring-Plough/DNAX Corp., San Francisco, CA, USA) and a colony was established to provide male 9-to 10-week-old mice for these experiments. The mutant IL23p19À/À mice are of B6 background. Research mice were housed in groups of four in microisolater cages in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care-certified facilities under the supervision of licensed veterinarians. Sentinel mice to detect viral and bacterial infections in the colonies were always present in the rooms with the breeding colonies and with the adult mice. All attempts were made to obtain healthy mice and minimize their discomfort.
Transplantation (hereafter referred to as TNX)
In these studies, we used our model of transplantation of H2 b donor cells into H2 d BALB/c hosts. 3, 4 Unless otherwise specifically stated, groups of 9-to 10-week-old male BALB/ c mice were exposed to 8.5 Gy TBI using a Mark IV 137-cesium irradiator (JL Shepard, Glendale, CA, USA) at a dose rate of 2.0 Gy/min. Within 1 h, they were transplanted with 10 Â 10 6 BM and 2.5 Â 10 6 spleen cells (SCs; equivalent to approximately 0.8 Â 10 6 T cells) from normal male syngeneic BALB/c, allogeneic wild-type (WT) B6 or allogeneic p19À/À donors. The mice were inspected and weighed daily; if they showed 420% loss of initial weight, they were weighed twice daily. Following our local guidelines and those of the Association for Assessment and Accreditation of Laboratory Animal Care, mice that met the following criteria were killed and counted as experimental deaths. The principal criteria included 'abnormal response to external stimuli, that is, slow or no movement after gentle prompting, abnormal ambulation, severe diarrhea, uncontrolled bleeding, seizures, skin ulcerations and rapid/panting respirations', and lesser ones included 'hunched posture, a loss of X2 g body weight within 48 h, abnormal hair, and exudates around the eyes and/or nose'. The presence of one of the principal or two of the lesser criteria constituted the criteria for killing.
Histology
At specified times, other groups of BALB/c mice transplanted with allogeneic and syngeneic cells were anesthetized and blood was obtained by cardiac puncture to determine the timing and levels of the selected cytokines. Next, the mice were killed and the spleen, skin, liver, small bowel and large bowel were excised. The tissues were stained with hematoxylin and eosin and examined for histological characteristics of aGVHD in the bowel: in the villi for crypt abscess, single-cell necrosis, mitotic figures and loss of epithelial cells; in the liver for inflammation and loss of bile ducts; and in the skin for pyknotic nuclear changes, degeneration and loss of hair follicles and sebaceous glands, thinning and focal loss of epithelium. Although the spleen does not show diagnostic changes of aGVHD, it was also examined to confirm the loss and gain of cells in the course of the transplantation.
Cell survival and recovery
In addition to histological changes, aliquots of the spleen were obtained for investigation of cytokine gene expression and for the absolute number of cells present at the times of analysis. The spleen was chosen because it contains a trilineage population of B lymphocytes, T lymphocytes, natural killer (NK) cells, granulocytes, macrophages, erythroid precursors and megakaryocytes. The weight of the spleen and the body weight at the time of killing were obtained for calculation of the Simonsen's ratio. The total number of leukocytes in the spleen was calculated by multiplying the total cell counts (determined by crystal violet staining) with the percentage of cluster of differentiation 45 (CD45) cells (determined by flow cytometry). After isolating and washing the spleen cells at 10 1C, they were suspended in 5-ml cold flow cytometry medium and counted using crystal violet (5%) and acetic acid (0.0125%), and then resuspended in flow cytometry medium at 20 Â 10 6 cells/ml. To prevent Fc binding, the cells were blocked with CD16/32 (MFCR00) for 5 min, after which they were incubated with anti-H2K b (AFG-885) and H2K
d (34-2-12) to determine the donor-vs-host origin of the cells. The antibodies used were CD3 (HM3401), B-cell/CD19 (RM7704), CD4 (MCD0401), CD8 (RM2204), Macrophage F4/80 (RM2920) and Granulocyte GR-1 (RM3004) from Caltag (Burlingham, CA, USA), and NK (DX) and common leukocyte antigen CD45 (55308) from BD PharMingen (San Diego, CA, USA). Isotype controls were hamster IgG (HM01), rat (R2a01, R2a04), rat IgG2b (R2b20, R2b04) and rat IgM (PharMingen G53-238). After incubation for 15 min on ice, two-color flow cytometry was used to measure the percentage of cells of each phenotype. The absolute number of each phenotypic subset was calculated by multiplying the calculated number of leukocytes with the percentage of the phenotype (determined by flow cytometry).
Gene regulation
A portion of each spleen was obtained on the scheduled days and immediately frozen. After clearing the homogenate lysate with ethanol, total RNA was isolated through Qiagen RNeasy columns (Qiagen, Valencia, CA, USA) and stored at À80 1C. The precipitate was washed with 70% ethanol and the quantity of ribosomal RNA was determined. Samples from each scheduled time were stored at 4 1C until the experiment was complete. Taqman Master Mix (Applied Biosystems, Forest City, CA, USA) was used to convert the RNA into cDNA. Using complete Taqman prequalified primer and probe expression assays (Applied Biosystems) for TNF-a (Mn00443258_m1), lL-1-b (Mm00434228_m1), IL-6 (Mm0046190_M10), IL-23p19 (Mm00518984_m1), IL-23/IL-12 p40 (Mm00434170_m1), transforming growth factor-b (TGF-b) (Mm00441724_m1), IL-17 (Mm0039619_m1) and IL-22 (Mm00444241_m1), the expression of the gene transcripts was measured in an Applied Biosystems 7500 Fast Real Time System and analyzed. The DCt method was used to normalize the transcripts to glyceraldehyde-3-phosphate dehydrogenase. The fold change was calculated by dividing the normalized experimental value by the normalized value for each set of transcripts, and the mean±s.d. of the samples was calculated for each day of analysis.
Serum cytokines
After separation of the serum, the samples were frozen and held until all of the time points were completed so that the levels of each cytokine at each of the time points could be analyzed together. Thereafter, the manufacturer's kit directions were followed for IL-17A (eBioscience, San Diego, CA, USA; 88-7971-29) and for IL-22 (R&D Systems, Minneapolis, MN, USA; Quantikine M2200).
Statistical analysis
The mean cytokine levels, mRNA levels and absolute cell counts were compared by using an analysis of variance for a 3 Â 10 factorial design with factors donor at three levels and the day of killing at 10 levels (4 h, and 1, 2, 3, 5, 7 and 10 days). Post hoc comparison of means was used to compare the donor groups at each day of killing, given that the interaction between the day of killing and donor was significant at the 0.05 level. As the group sizes were sometimes slightly unbalanced due to the loss of mice killed later, least squares means was used in these comparisons. Log rank statistics were used to compare survival of the different experimental groups. Po0.05 was taken as significant.
Results
The incidence and severity of aGVHD in BALB/c mice transplanted with H2 b p19À/À BM þ SCs was less than that when the donor cells were from WT H2 b B6 cells BALB/c mice were transplanted with syngeneic, allogeneic B6 or allogeneic p19À/À BM þ SCs. All of the syngeneic transplanted mice lost a little weight (mean ¼ 1.207À/ À3.1 g) between days 3 and 7 post transplant, but most of them regained that weight and all but 2/21 (90.5%) survived for the observation period ( Figure 1a ). However, a majority of the BALB/c mice transplanted with both allogeneic WT B6 and p19À/À BM þ SCs developed aGVHD and suffered weight loss by day 7: B6 donors (mean ¼ 8.34 ± 1.89 g; Po0.0001 when compared with syngeneic controls) and p19À/À donors (mean-5.95±3.80 g; Po0.001 when compared with the syngeneic controls). The mice in both groups showed clinical signs of aGVHD, including hunched posture, diarrhea and lethargy. Few of the mice transplanted with p19À/À cells showed no clinical signs of aGVHD. Histologically, the major finding correlating with severity in the killed mice was severe mucosal injury, including marked loss of villi in both the small and large bowel. The liver was normal in both groups. The mice that met the Animal Component of Research Protocol-approved criteria were killed and were counted as experimental deaths. Thus, by day 9, 12 of the BALB/c mice transplanted with B6 and 5 of those transplanted with p19À/À were declared dead. The apparent mean increase in weight in the B6 survivors after day 9 reflects the fact that the sickest of the mice had died during the interim period. By day 30, survival ( Figure 1b) of those mice transplanted with p19À/À cells (30/ 40 ¼ 75%) was highly statistically greater than those transplanted with B6 cells (3/25 ¼ 12%) (Po0.0001).
Another useful surrogate criterion for aGVHD is the ratio of the weight of the spleen divided by body weight Â 1000, termed Simonsen's index. High ratios are indicative of aGVHD ( Figure 2 ). The mean Simonsen's indices on day 7 post transplant were 1.7 ± 0.45 (n ¼ 9) for syngeneic, 4.6 ± 0.72 (n ¼ 11) for allogeneic B6 and 3.16±0.61 (n ¼ 9) for allogeneic p19À/À. Simonsen's index of the B6 transplanted mice (a, 4.6±0.72) was significantly greater (P ¼ 0.0028) compared with the index of the p19À/À mice (aa, 3.16 ± 0.61). By day 14, all of the B6 transplants had died in this experiment. Although the Simonsen's index had returned to that of the syngeneic controls by day 36 (Figure 2 ), lymphoid follicles in the spleens of the surviving p19À/À mice were reduced in size as compared with the controls, but both erythropoiesis and, particularly, myelopoiesis were quite active.
IL-17 mRNA is markedly increased in the BALB/c mice transplanted with allogeneic cells but less so in mice transplanted with p19À/À BM þ SCs To address the issue as to why BALB/c mice transplanted with p19-deficient BM þ SCs developed less severe aGVHD and survived to a significantly greater degree than those transplanted with B6 BM þ SCs, we correlated the kinetics of cell loss or recovery after lethal TBI alone and allogeneic transplantation with the gene expression of some of the principal cytokines. We chose to measure mRNA to determine the relative expression of these genes in relation to clinical symptoms and to one another. This choice was in part based on the possibility that detection of a serum cytokine may be obscured by the sensitivity of the assays and/or binding with its receptor(s). Groups of BALB/c recipients were transplanted with 10 Â 10 6 BM þ 2.5 Â 10 6
SCs from each donor group and were autopsied at 3, 5, 7 and 10 days after transplantation. The spleen was excised and weighed. One-half of the spleen was dispersed for determination of the absolute number of cells present at these time points (Table 1) . At day 3, early engraftment of both B6 (21.78±8.78%) and p19À/À (26.86±2.12%) cells was evident. By day 5, both B6 and p19À/À H2 b donor cells had increased to 96% and by day 7 virtually all of the cells in the spleen were of donor origin.
The other portion was used for gene expression. The relative mRNA fold change represents the mRNA in 50 ng/ml total RNA of the experimental sample compared with that of an untreated control. Figure 3 illustrates a significant rise in mRNA p19 by day 7 in BALB/c mice transplanted with B6 donor cells: (aa) vs (a) (P ¼ 0.0986). In addition, it confirms the fact that there was no significant expression of p19 mRNA in the spleen of mice transplanted with p19À/À BM þ SCs. Surprisingly, there was a profound increase in the expression of IL-17 mRNA by days 3 and 5 in both the B6 TNX and p19À/À TNX mice. However, although markedly elevated, the peak elevation on day 5 was significantly less in the p19-deficient cells (bb ¼ 275-fold) than in the B6 cells (b ¼ 943-fold) (Po0.0095). When considered in the context that mRNA for TNF-a was only upregulated threefold in the same mice (data not shown), the upregulation of IL-17 suggests that it may have a major role in the pathogenesis of the subsequent pathology of aGVHD. Table 1 documents the absolute number of leukocytes in the spleen and the kinetics of their changes in the spleen on days 3, 5, 7 and 10 post transplantation. Several key features are evident. There was a sharp rise in B6 (P ¼ 0.0041) or p19À/À (P ¼ 0.0003) CD3/CD8 þ T cells on day 5 when compared with their levels on day 3. In contrast, there was no significant elevation of CD3/CD4 B6 T cells at any time point. On day 5, there was a modest but statistically significant increase in CD3/CD4 p19 cells. However, the elevations of both CD3/CD8 B6 (P ¼ 0.0079) and p19 (P ¼ 0.0011) cells were significantly greater than that of the CD3/CD4 B6 and p19 cells on day 5. At every time point the sum of CD4 þ and CD8 þ T cells essentially equaled the number of CD3 þ T cells, indicating that there were virtually no CD4À and/or CD8À CD3 þ cells in these spleens that could have reflected a g/d T-cell population. Gr-1 granulocytes increased progressively from day 5 to day 10. Figure 4 illustrates these key phenotypic changes in relation to dramatic increases in mRNA and serum IL-17. Note that serum IL-17 was maximally elevated on day 5, declined by day 7 and reached baseline by day 10 in both B6 TNX and p19 TNX BALB/c mice. However, it was significantly higher on day 5 in the B6 as compared with p19 TNX mice: (aa) vs (a) (Po0.0357) The days of maximal upregulation of IL-17 mRNA and the corresponding cytokine levels suggest an association with the onset of mice death beginning on day 6 post TNX ( Figure 1b) . In contrast, the time of first increase and subsequent rise in splenic granulocytes through day 10 in B6 and to a greater degree in the mice transplanted with p19À/À cells (P ¼ 0.0222) suggest that they may have been stimulated by the previous increase in IL-17 and not associated with the difference in survival.
TBI upregulates IL-6, IL-23p19 and TGF-b in BALB/c mice Taken in the context of the documented role of p19 in the sustained induction of IL-17-producing cells, these data raised the question as to the source of stimuli for the great increase in IL-17 mRNA in the BALB/c mice transplanted with cells deficient in p19. One possibility was that IL23p19, IL-6 and TGF-b were upregulated by TBI itself in host cells and thus were able to induce Th17 in the incoming donor T cells. To address this question, BALB/c mice were given 8.5 Gy TBI but no transplant. At 4, 24, 48 and 120 h, groups of three mice were killed and autopsied. These times were selected on the basis of the early increases in serum TNF-a, IL-1b and IL-6 levels that we had reported after transplantation 3 and on the onset of apoptosis in the small bowel and spleen within 4 h after 8.5 Gy TBI (data not shown). One-half of the spleen was taken for determination of the surviving cells and the other half for expression of these genes. Although the numbers of T cells and granulocytes were markedly reduced after 48 h, macrophages and NK cells persisted through 120 h. The viable cells remaining at these times were functionally active and significant upregulation of the mRNA of key cytokines occurred by 48 h after TBI (Figure 5a ). Note the marked upregulation of p19 mRNA apparent at 48 and 120 h after TBI. In addition to p19, mRNA IL-6 and TGFb were also upregulated sixfold after TBI. 6 and counted by a hemocytometer by the % CD45 ¼ total leukocytes; and by the % CD19 ¼ B cells; % CD3, CD4 and CD8 ¼ T cells; % Gr-1 ¼ granulocytes; % NK ¼ natural killer cells; and % F4/80 ¼ monocytes/macrophages. and 4). As a control, IL-17 and p19 gene expression were also tested after 8.5 Gy TBI of p19-deficient mice and no upregulation of either cytokine was detected (data not shown). Figure 5b illustrates other important findings. As expected, p19 was not induced when p19 BM and SCs were transplanted, but it was induced when the donor cells were from WT B6 donors (also see Figure 3 ). Whereas IL-6 mRNA was elevated post transplantation in both, TGF-b was not upregulated in either B6 or p19 donor cells.
IL-6 upregulation in the absence of TGF-b in the donor favors the development of Th17 cells and inflammation
IL-22 may not be a major factor in the pathogenesis of aGVHD induced in BALB/c mice transplanted with allogeneic p19À/À cells IL-22 is another cytokine produced not only by Th17 cells but also by NK cells. IL-23 has a key role in its regulation. IL-22 mRNA increased more than twofold by 120 h: (aa) vs (a) (P ¼ 0.0080) and serum IL-22 also significantly increased after TBI-only by 48 h: (bb) vs (b) (P ¼ 0.0008) and remained elevated at 120 h ( Figure 6 ). Its expression was significantly increased at day 3 in BALB/c mice transplanted with B6 cells: (aa) vs (a) (P ¼ 0.0015) and was markedly increased after transplantation with p19À/À cells: (aaa) vs (a) (Po0.0001). It was markedly elevated on day 3 after transplantation with either B6 or p19 donor cells: (dd) and (ddd) vs (d) (Po0.0001). However, IL-22 mRNA decreased to baseline by day 5 and serum IL-22 to baseline by day 7. These changes in IL-22 gene expression and serum cytokine level appear to correlate with the fact that 79% of the host H2 d cells were still present in the spleen on day 3, decreased to only 4% by day 5 and were essentially absent by days 7 and 10.
Discussion
To summarize, the survival of H2
d BALB/c mice transplanted with H2 b p19-deficient BM þ SCs was strikingly superior to that of BALB/c mice transplanted with H2 b WT B6 BM þ SCs. Mice transplanted with both p19À/À and B6 BM þ SCs lost weight and showed characteristic changes of aGVHD in the bowel and skin. However, both the histology and the Simonsen's index showed that the improved survival in the recipients of p19À/À cells was associated with less severe inflammation than those transplanted with B6 cells. As expected, the expression of p19 was absent in the mice transplanted with p19À/À cells, but IL-17 gene expression was markedly elevated in both the B6 and p19À/À donor groups. Notably, IL-17 gene expression and serum levels were significantly greater in the mice transplanted with the WT cells. The fact that IL-17 was so strongly upregulated in p19À/À donor cells raised the question as to how it was upregulated in these cells that lacked the capacity to produce IL-23p19. Although it has not been proven, the observation that TBI alone upregulated TGF-b, IL-6 and IL-23p19 in BALB/c mice suggests that they may have provided the necessary stimulus for the upregulation of Th17 and/or other cells producing IL-17 in donor spleen cells.
Initially, it was thought that Th17 cells were predominately, if not exclusively, CD4 T lymphocytes, but it is now clear that TGF-b and IL-6 can also stimulate a subset of Th17 CD8 lymphocytes, through RORg t. [41] [42] [43] With the exception of a small but significant increase in p19 donor cells on day 5, CD3 þ /CD4 þ T cells were not significantly increased in our study, suggesting, but not confirming, that donor CD8 þ Th17 cells were the principal source of IL-17 in this transplant model. IL-6 cascade? There are several isomers of IL-17. 22, 23 Of these, the most studied are IL-17A and IL-17F. IL-17A has been reported to stimulate IL-6, IL-8 and granulocytecolony-stimulating factor and enhance the expression of the intercellular adhesion molecule. IL-17F has been reported to stimulate IL-6, IL-8, G-CSF, GM-CSF, TGF-b, monocyte chemotactic protein-1, GRO-a and ENA. Human Th17 cells also coexpress TNF-a 23 and it may be so in mice also. 13 Conversely, IL-1b and to a lesser degree TNF-a stimulate p19 production through activation of nuclear factor-kB. 16, 18, 19 Taken together, the ability of the IL-23/ p19/IL-17 axis to influence many other inflammatory molecules makes it a potentially major factor in the inflammatory reactions of aGVHD. IL-6 and TGF-b are essential for the development of Th17 in the mouse. 44, 45 TGF-b has a central role in the differentiation of naive T cells to become regulatory T cells 44 or under the influence of IL-6, [44] [45] [46] through the orphan nuclear receptor RORg t, to become Th17 proinflammatory cells. Given this observation, the fact that IL-6 mRNA was upregulated and TGF-b was not in either B6 or p19 transplanted mice ( Figure 5 ) supports the conclusion that IL-17-secreting Th17 cells, rather than regulatory T cells, were favored. Taken together, these cross-talking signals create the potential for a continuing interrelated inflammatory circuit. As TBI activates NF-kB and upregulates both TNF-a and IL-1b, 3 it is possible that TBI and other oxidant stresses might upregulate IL23p19. There have been no previous reports to this effect, but our data clearly show the marked upregulation of mRNA p19 in BALB/c mice after administration of 8.5 Gy TBI.
Several recent papers illustrate the controversy regarding the role of Th17 cells and its products in the pathogenesis of aGVHD. [35] [36] [37] [38] [39] IL-17 was found to have a prominent role in the inflammatory process. [35] [36] [37] [38] Chen et al. 34 concluded that uncontrolled Th1 and Th17 cells had a major role in the pathogenesis of chronic GVHD. Carlson et al. 38 showed that in vitro polarized B6 Th17 cells induced marked cutaneous and pulmonary pathological changes after transplantation into B6D2 (C57Bl6/DBA2) hosts. When the polarized Th17 donor cells were derived from IFN-g À/À animals, severe skin lesions still occurred. However, Das et al. 39 concluded that IL-17 was not responsible for colonic injury in BALB/c mice transplanted with either B6 or IL-23À/À BM þ SCs. They observed that there were relatively few CD4 þ IL-17 secreting cells in the colon in contrast to IFN-g-producing cells. When the donor cells were obtained from IL-23À/À or IFN-g À/À, the colonic pathology was less severe. On the basis of these findings, Das et al. concluded that aGVHD in the colon of their animals was independent of IL-17 and emphasized the role of IFN-g in the pathology. Although earlier studies implicated IFN-g as a proinflammatory factor in the pathogenesis of aGVHD, 47, 48 several other studies have shown that it has an inhibitory effect on aGVHD by suppressing T-cell proliferation. 49, 50 Recently, Mauermann et al. 36 reported that the absence of IFN-g was associated with an increased induction of Th17 CD4 þ T cells, local IL-17A release and severe disease. These varied results [35] [36] [37] [38] [39] may be a reflection of the several different experimental models that were tested, including fully allogeneic, semiallogeneic and minor histocompatible mismatched transplants. The most similar model to ours is that by Das et al., 39 in which host BALB/c mice were transplanted with either WT B6 or IL-23À/À BM þ SCs. However, the deficiency of the p40 dimer as well as of p19 in the IL-23À/À donor cells may have contributed to an independent effect on the outcome of the transplants. For example, we have observed an increase in serum IL-12/ IL-23 p40 of nearly fourfold by day 28 in surviving BALB/c mice transplanted with p19À/À cells, some of which subsequently developed skin changes consistent with chronic GVHD (data not shown).
Another important cytokine that is produced not only by Th17 cells but also by NK cells is IL-22. 51 Similar to IL-17, IL-23 is required for early induction of IL-22. 52, 53 In addition to IL-23 and IL-17, recent studies have shown that IL-22 may be a major factor in the pathogenesis of psoriasis 54 and in inflammatory bowel disease. 55 As both the skin and bowel are target organs in aGVHD, the question arises as to the role of IL-22 in aGVHD. Our data show that TBI alone upregulated IL-22 in BALB/c spleen cells. However, the upregulation of IL-22 mRNA was detected only on day 3 in the transplanted mice and elevated levels of serum IL-22 cytokine were maximal on day 3 and absent by day 7. This raises two questions. thereafter, they were replaced by donor H2 b cells. This suggests that the WT and p19À/À donor cells, which had not been radiated, did not produce IL-22. The fact that IL-17 mRNA expression in the spleen peaked on day 5 and persisted at lower but still significant levels through day 10 in B6 spleens indicates that donor H2 b cells were producing this cytokine. Taken together, these data strongly support the possibility that IL-17 and IL-22 were produced by different cells and/or the duration of their stimuli was different. (2) What role, if any, does IL-22 have in the inflammation of aGVHD? The data suggest that IL-22 may not be a sustaining factor in the evolution of aGVHD.
If not, what effect could its absence have on the outcome? To date, the effect of IL-22 deficiency on aGVHD has not been reported. A recent study 56 has shown that its absence by day 7 post transplant led to accelerated rejection of heart grafts. With this in mind, it is possible that IL-22 may sometimes have an inhibitory effect and its absence in donor cells may have enhanced the severity of aGVHD.
Finally, could the improved survival of mice transplanted with p19À/À BM þ SCs be related to still another consequence of the absence of this factor? Iwakura and Ishigame 28 noted that anti-IL-17 was not as effective as either anti-IL-23p19 or anti-IL-12 antibody in preventing the onset or relapse of experimental allergic encephalitis and concluded that IL-23p19's effect on it was through an IL-17-dependent and an IL-17-independent IL-1/IL-6 pathway. In these experiments, IL-1 mRNA was not significantly upregulated but IL-6 mRNA was upregulated in both the B6 and p19 transplanted mice.
Looking forward
Taken together, the reports cited above and others not cited continue to reflect the fact that there is still no consistently reliable way to treat and/or prevent GVHD and preserve the GVL effect. The information regarding more newly characterized cytokines, which may be involved in the signaling pathways leading to GVHD, offers new experimental and potentially clinical approaches to improve the outcome. One of these is the seminal role that IL-23 dimer, termed p19, may have in the pathogenesis of aGVHD. The results presented herein and in the literature suggest two new approaches to therapy, that is, preventive antibody therapy directed at IL-17 57 and IL-23p19. 13, 58 
